Hypertension is a common trait of multifactorial determination imparting an increased risk of myocardial infarction, stroke, and end-stage renal disease. The primary determinants of hypertension, as well as the factors which determine specific morbid sequelae, remain unknown in the vast majority of subjects. Knowledge that a large fraction of the interindividual variation in this trait is genetically determined motivates the application of genetic approaches to the identification of these primary determinants. Success in this effort will afford insights into pathophysiology, permit preclinical identification of subjects with specific inherited susceptibility, and provide opportunities to tailor therapy to specific underlying abnormalities. To date, mutations in three genes have been implicated in the pathogenesis of human hypertension: mutations resulting in ectopic expression of aldosterone synthase enzymatic activity cause a mendelian form of hypertension known as glucocorticoidremediable aldosteronism; mutations in the .3 subunit of the amiloride-sensitive epithelial sodium channel cause constitutive activation of this channel and the mendelian form of hypertension known as Liddle syndrome; finally, common variants at the angiotensinogen locus have been implicated in the pathogenesis of essential hypertension in Caucasian subjects, although the nature of the functional variants and their mechanism of action remain uncertain. These early findings demonstrate the feasibility and utility of the application of genetic analysis to dissection of this trait.
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Hypertension as a Complex Genetic Trait
Hypertension is a common trait affecting 50 million Americans and contributing to over 200,000 deaths annually from stroke, myocardial infarction, and end-stage renal disease. Despite extensive physiologic investigation, the primary determinants of this trait, as well as the factors which determine specific clinical outcomes, remain unknown in the overwhelming majority of affected subjects. This ignorance results in reduced efficacy of therapy and hinders efforts to prevent morbid outcomes.
Knowledge that a large fraction of interindividual variation in blood pressure is genetically determined suggests the use of genetic approaches in identification of primary determinants of human hypertension. The premise of such efforts is that identification of genetic determinants of human hypertension will provide key leads in unraveling the pathogenesis of this trait, will permit identification of individuals with specific underlying inherited predisposition, and ultimately may permit intervention in either preclinical or clinical stages with therapy tailored to these underlying abnormalities. All lines of evidence are concordant in supporting the influence of heredity on blood pressure: twin studies reveal a greater concordance of blood pressure in monozygotic twins than in dizygotic twins (1); epidemiologic studies reveal highly significant familial aggregation of blood pressure (2) , which is not merely due to effects of shared environment since biological siblings have greater concordance of blood pressure than adoptive sibilings raised in the same household (3) . Such studies estimate that 20-40% of the variation in blood pressure in the population is genetically determined, with recent studies using more realistic models of inheritance providing generally higher estimates of heritability (4, 5) .
Despite this evidence of a large effect of inheritance on blood pressure, these same studies suggest that blood pressure is commonly multifactorial in determination, since (i) blood pressure does not typically segregate in families in a fashion consistent with mendelian transmission and (ii) a variety of other factors such as salt intake, age, gender, and body mass can chronically influence blood pressure. It is popular to presume that the blood pressure in individual patients is due to the combined effects of variation at a number of blood pressure-determining loci, environmental factors, and demographic factors (Fig. 1) . The number of loci in which variants affect blood pressure in humans, the magnitude of the effects imparted by each locus, and the model of inheritance at each trait locus are not readily estimated, providing little guidance for how best to approach identification of these loci. These uncertainties pose strategic problems which are encountered in other complex traits such as diabetes, asthma, 8545 atherosclerosis, and neuropsychiatric disorders.
Approaches to Identification of Trait Loci
Owing to these uncertainties, it is difficult to determine the optimal approach to identification of trait loci affecting blood pressure in humans. A (14) .
In the setting of multifactorial determination, linkage studies using hypertension as a dichotomous trait in affected relative pairs retain considerable power to identify the chromosomal position of trait loci (15) (16) (17) (18) (25) . The strength of this finding arises from the replication in independent patient samples of mutually reinforcing lines of evidence.
In both the Salt Lake City and Paris hypertensive sib pair sets, linkage of a highly informative marker at the angiotensinogen locus and hypertension was found in more severely affected sib pairs [defined as sibs having diastolic blood pressures > 100 mm Hg (1 mmHg = 133 Pa) or requiring two or more antihypertensive medications for control of blood pressure]. In both groups, there was >15% excess allele sharing in the hypertensive siblings compared with the allele sharing expected under independent assortment (P < 0.001). These findings motivated a search for molecular variants in the angiotensinogen gene; the prevalence of identified variants was then compared in cases and controls from these two populations. One of these identified variants, in which a threonine residue was substituted for methionine at codon 235 of the angiotensinogen gene, was found to be significantly more prevalent in hypertensive subjects than in normotensive subjects in both the Salt Lake City and Paris patient populations, with a prevalence of 36% in controls and 47% in unrelated index cases (P < 0.001) and 51% in more severely affected index cases (P < 0.001).
These findings 'supporting linkage and association of variants in the angiotensinogen gene with hypertension leave open the question of the mechanism by which such variants might affect blood pressure. The active hormone angiotensin II is produced from angiotensinogen by sequential cleavage steps by renin and ACE (Fig. 2) . In response to contracted intravascular volume, the renal juxtaglomerular cells secrete more renin, resulting in increased formation of angiotensin II. Evidence suggesting a potential role of variation in plasma angiotensinogen levels in blood pressure determination has been present for many years (26, 27) . In addition, however, it has long been recognized that plasma angiotensinogen levels are poised near the Km for cleavage by renin, with the consequence that alteration of angiotensinogen levels also affects the formation of angiotensin II. These findings raised the possibility that inherited vari- ants at the angiotensinogen locus might act via alteration in plasma angiotensinogen levels. Examination revealed that the same variants in disequilibrium with hypertension were also associated with elevated plasma angiotensinogen levels; again, these findings were replicated in the Salt Lake City and Paris populations and were highly statistically significant (P < 0.0001) (25) .
These findings constitute evidence that common variants at the angiotensinogen locus contribute to elevated blood pressure. At present, the identity of the true functional variant(s) at this locus is uncertain; T235 could represent such a functional variant or, alternatively, could be in disequilibrium with the true functional variants in these populations. As a consequence of this uncertainty, the proportion of alleles bearing T235 which impart an effect on blood pressure is unknown, and the magnitude of the effect imparted by each functional variant cannot be determined. Similarly, the mechanism by which such variants lead to altered angiotensinogen levels is unresolved. These variants could in principle act either by increasing the synthesis/secretion of angiotensinogen from the liver or by prolonging the plasma half-life of the protein. Further work will be required to distinguish between these possibilities and to establish the precise mechanisms by which variants affect blood pressure. At present, several important confirmations have appeared, ranging from linkage disequilibrium of angiotensinogen alleles and hypertension in several populations (28, 29) to demonstration of variation in blood pressure in mice as a function of the number of angiotensinogen gene copies (30) . It appears that common variants at the angiotensinogen locus have a modest effect on blood pressure, as expected under a model of multifactorial determination.
Mendelian Forms of Human Hypertension. At present, four mendelian forms of human hypertension are recognized in which mutation in a single gene leads to elevated blood pressure in a high proportion of affected subjects: GRA (31), Liddle syndrome (pseudoaldosteronism) (32), pseudohypoaldosteronism type II (Gordon syndrome) (33) , and the syndrome of apparent mineralocorticoid excess (AME) (31) . Each of these disorders was initially recognized because of the presence of the precocious onset of hypertension in conjunction with abnormalities in electrolyte handling. As has been the case for mendelian forms of other complex traits such as colon cancer, breast cancer, and diabetes, genetic analysis of these single-gene forms of hypertension will likely be most rapid. Understanding these disorders will be of importance to the families that are affected and also will provide insight into basic mechanisms contributing to blood pressure variation which may prove broadly relevant to hypertension in the general population. The molecular bases of two of these disorders, GRA and Liddle syndrome, have been defined. The molecular bases of pseudohypoaldosteronism type II and AME are under investigation.
GRA. GRA is an autosomal dominant trait characterized by hypertension mediated via the mineralocorticoid receptor (34, 35) . Affected subjects have variably elevated plasma aldosterone levels in conjunction with suppressed plasma renin activity and secrete high levels of two steroids that unaffected individuals produce in negligible amounts: 18-oxocortisol and 18-hydroxycortisol (36) (37) (38) . The physiologic sine qua non of GRA is now recognized to be the positive regulation of the secretion of aldosterone and these abnormal steroids by adrenocorticotropic hormone (ACTH) rather than the normal secretagogue for aldosterone, angiotensin II. A large GRA kindred phenotypically classified on the basis of 18-oxocortisol secretion demonstrated patent autosomal dominant segregation of this intermediate biochemical phenotype in the kindred (39) . Linkage studies in this family demonstrated linkage of the gene causing GRA to a segment of chromosome 8 harboring a candidate gene, the aldosterone synthase locus (40) . The aldosterone synthase gene is normally expressed in adrenal glomerulosa, where its gene product catalyzes the last two steps in the biosynthesis of aldosterone. This gene is 95% identical in DNA sequence to another gene involved in steroid biosynthesis, the steroid 11,-hydroxylase gene (41) (42) (43) , which is involved in the biosynthesis of cortisol in adrenal fasciculata; both of these genes are present on chromosome 8, and it is now known that the two genes are very tightly linked, separated by only about 45 kb in genomic DNA (44) . Investigation of these genes in this extended kindred demonstrated the presence of a novel mutation-unequal crossing-over between aldosterone synthase and 11-hydroxylase genes had resulted in a chimeric gene duplication fusing proximal sequences of 11-hydroxylase onto more distal sequences of aldosterone synthase (Fig. 3) (40) . This mutation cosegregates with the disease at a recombination fraction of zero.
The physiologic consequences of this mutation explain the clinical features observed in affected individuals (40) (Fig. 4) . Owing to 5' regulatory sequences from the 11-hydroxylase gene, this chimeric gene is expected to be expressed in adrenal fasciculata under control of ACTH. Due to coding sequences from aldosterone synthase, however, it is anticipated that the encoded product will have aldosterone synthase enzymatic activity, with the consequence that this mutation results in ectopic expression of this critical enzyme in salt and water homeostasis. As a result, aldosterone is produced from corticosterone in adrenal fasciculata rather than adrenal glomerulosa; in addition, the signature steroids of GRA, 18-oxocortisol and 18-hydroxycortisol, are produced by the action of this enzyme on cortisol, which is normally synthesized in fasciculata. Aldosterone secretion leads to salt and water retention and, hence, plasma volume expansion. This volume expansion in turn suppresses plasma renin activity and turns off production of angiotensin II; however, this fails to suppress secretion of mineralocorticoids, since these are now under control of ACTH rather than angiotensin II; this unrestrained secretion of mineralocorticoids results in sustained volume expansion and hypertension.
Additional GRA kindreds have been examined, and all have been found to have similar chimeric gene duplications arising from unequal crossing-over (44, 45) . The site of crossing-over has been variable, ranging over a 2-kb segment from the second intron to the fourth intron of these genes. In each case, exon 5 has been encoded by the aldosterone synthase gene, suggesting that this exon contains critical residues for producing aldosterone synthase enzymatic activity (44, 45 (45) .
These findings establish the molecular basis of a mendelian form of human hypertension. Mutations arising from unequal crossing-over are also found in thalassemias (46), red-green color vision blindness (47) , and congenital adrenal hyperplasia due to 21-hydroxylase deficiency (48) ; however, these other disorders are typically characterized by loss of function due to gene deletion, rather than gain of function from the allele bearing duplications.
These findings afford the opportunity to define the consequences of inheritance of a specific mutation on blood pressure and clinical outcome. Early experience with this disease has revealed a striking predilection for one clinical outcome in these kindreds: cerebral hemorrhage at very early ages (39) . This finding has been present in multiple individuals of a number of studied kindreds, suggesting that these mutations predispose to this particular clinical outcome.
Further investigation of kindreds with this disorder will also provide the opportunity to begin to define the quantitative effects of inheritance of this gene on blood pressure. Examination of the variability in phenotypic expression of affected subjects inheriting the same mutation by descent from a common ancestor may provide insight into the prevalence and action of other alleles in the population which affect blood pressure, and also afford new opportunities to study gene-environment interaction.
The molecular basis of GRA suggests that a simple test for these characteristic gene duplications can be applied to a small blood sample. This testing is likely to be applicable to pediatric subjects with unexplained hypertension, to subsets of the adult population with refractory hypertension or signs of aldosteronism in which aldosterone-producing adenoma and adrenal hyperplasia are excluded, and to at-risk relatives of affected subjects. The importance of making the diagnosis is that identified subjects are commonly classified as having refractory hypertension; however, once the diagnosis is made, they can be treated with a number of specific agents directed toward the primary abnormality. For (49) . It was found that 18 subjects had the diagnosis of hypertension prior to age 20, suggesting use of this trait for linkage studies. Such studies ultimately identified linkage of Liddle syndrome to a short segment of chromosome 16 , with a logarithm-of-odds score of 9.0 (50). In parallel, an amiloride-sensitive epithelial sodium channel was cloned: this channel was found to be composed of three subunits of similar structure-each contains two membrane-spanning domains, an extracellular loop, and intracellular amino and carboxyl termini (51, 52) . The human homologs of these subunits were cloned, and one of these, the 13 subunit, was localized to the same segment of chromosome 16 as the gene for Liddle syndrome (50) . Examination of this gene in five Liddle syndrome kindreds demonstrated that all five had mutations in a 95-bp segment encoding the proximal segment of the cytoplasmic carboxyl terminus; these mutations were not found in 250 control subjects. All of these mutations introduce either premature stop codons or frameshift mutations which remove 45-75 amino acids of the normal carboxyl terminus of the encoded protein (50) (Fig. 5) .
The finding of these characteristic mutations in the (3 subunit of the epithelial sodium channel in patients with Liddle syndrome, in conjunction with the physiologic characteristics of affected subjects, strongly suggested that these mutations result in constitutive activation of channel activity, leading to increased renal salt and water reabsorption independent of mineralocorticoid action, leading to volume expansion and hypertension. Expression of wild-type and mutant channels inXenopus oocytes has permitted testing of this hypothesis. Expression of the a subunit of the epithelial sodium channel alone results in low levels of amiloride-sensitive sodium channel activity; this activity is greatly augmented by coexpression of the (3 and 'y subunits, to levels which are similar to those seen in vivo (51, 52) . Expression of heterotrimeric channels containing the truncated ( subunit results in a marked increase in sodium channel conductance, demonstrating that the molecular mechanism of Liddle syndrome is constitutive activation of this channel (53) . Moreover, these findings implicate the cytoplasmic carboxyl terminus of the (3 subunit in the normal negative regulation of this channel (50, 53) . Interestingly, similar truncation of the 'y subunit, but not of the a subunit, also resulted in activation of channel activity (53) . Coexpression of truncated (3 and 'y subunits together resulted in further additive activation of the channel, indicating that each of these two subunits is involved in the normal negative regulation of channel activity and that these mechanisms must act independently or at least in parallel (53 In addition to these studies to identify determinants of hypertension, additional studies can be contemplated to identify determinants of particular clinical end points such as stroke, end stage renal disease, and myocardial infarction. The consolidation of health care into large networks in the United States may provide unique opportunities for ascertainment of large numbers of multiplex families with such specific end points. Genetic studies in such populations provide opportunities to determine whether specific genes affect clinical outcomes in individual patients; if found, these genes may provide opportunities for therapeutic intervention.
As functional variants are identified, their quantitative effects on blood pressure and their impact on clinical outcomes can be assessed by studies of the general population or by linkage in extended families. Opportunities will arise for evaluation of gene-gene and gene-environment interaction, and a renewed need for physiologic studies will be apparent. The opportunity to develop appropriate animal models based on identified functional variants, as well as to study the physiology of patients harboring different combinations of variants at trait loci, will likely provide important insights into the pathogenesis and treatment of hypertension and its complications.
Note Added in Proof. Since submission of this review, mutations in two additional genes have been implicated in human hypertension, demonstrating the rapid pace of this field. Mutations resulting in loss of function of the renal isozyme of 1103-hydroxysteroid dehydrogenase have been shown to cause the autosomal recessive syndrome of apparent mineralocorticoid excess (55) . This enzyme normally converts cortisol to cortisone, thereby preventing cortisol from activating the type I mineralocorticoid receptor in the kidney. Loss of this enzymatic activity results in cortisol acting as a potent mineralocorticoid. A mutation truncating the cytoplasmic carboxyl terminus of the y subunit of the epithelial sodium channel of the distal nephron has been shown to result in constitutive activation of channel activity, leading to increased sodium reabsorption and hypertension. This finding demonstrates genetic heterogeneity of Liddle syndrome (56) .
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